Causes of Botulinum Toxin Treatment Failure.
[PURPOSE] The purpose of this article is to review the cause of botulinum toxin (BT) failure and determine the ways to minimize the risks of its occurrence.
APA
Shtefan V, Fletcher J, Duclos OA (2022). Causes of Botulinum Toxin Treatment Failure.. Clinical, cosmetic and investigational dermatology, 15, 1045-1049. https://doi.org/10.2147/CCID.S363321
MLA
Shtefan V, et al.. "Causes of Botulinum Toxin Treatment Failure.." Clinical, cosmetic and investigational dermatology, vol. 15, 2022, pp. 1045-1049.
PMID
35698547
Abstract
[PURPOSE] The purpose of this article is to review the cause of botulinum toxin (BT) failure and determine the ways to minimize the risks of its occurrence.
[METHODS] A PubMed and Google Scholar literature search was conducted with the search terms botulinum toxin, treatment, failure, causes, and prevention. Fifteen relevant articles were found and used as the scientific base for this article.
[RESULTS] The failure of BT therapy is associated with immunogenic and non-immunogenic causes and the formation of neutralizing antibodies toward the active components of BT or the complexing proteins. Enzyme-linked immunosorbent assay (ELISA) testing and mouse hemidiaphragm assay (MHA) can diagnose the failure. The risk of developing treatment failure can be minimized by using complexing protein-free formulations, selecting a treatment regimen with the least immunogenicity, proper injection technique, and gentle product handling.
[CONCLUSION] The treatment failure can compromise the success of BT treatment. Current medical literature shows controversial evidence for and against BT immunogenicity. Therefore, the cause of BT failure is likely to be multifactorial.
[METHODS] A PubMed and Google Scholar literature search was conducted with the search terms botulinum toxin, treatment, failure, causes, and prevention. Fifteen relevant articles were found and used as the scientific base for this article.
[RESULTS] The failure of BT therapy is associated with immunogenic and non-immunogenic causes and the formation of neutralizing antibodies toward the active components of BT or the complexing proteins. Enzyme-linked immunosorbent assay (ELISA) testing and mouse hemidiaphragm assay (MHA) can diagnose the failure. The risk of developing treatment failure can be minimized by using complexing protein-free formulations, selecting a treatment regimen with the least immunogenicity, proper injection technique, and gentle product handling.
[CONCLUSION] The treatment failure can compromise the success of BT treatment. Current medical literature shows controversial evidence for and against BT immunogenicity. Therefore, the cause of BT failure is likely to be multifactorial.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 3 |
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.